HER2 no câncer colorretal

por Jason Wasserman MD PhD FRCPC
19 de novembro de 2026


Imprima este artigo

HER2 is a protein on the surface of cells that tells them to grow. In a small number of colorectal cancers, the cancer cells have extra copies of the gene that makes HER2. They then make far too much of the protein. These cancers are called HER2-positivo. If a HER2-positive colorectal cancer has spread, drugs that target HER2 may help.

This article explains what a HER2 result means on your report, how the test is done, and how the result may affect your treatment.

O que é HER2 e o que faz

HER2 in colorectal cancer works like an antenna on the cell surface. It picks up signals that tell the cell to grow and divide. When a cancer cell has extra copies of the HER2 gene, it makes far too much HER2 protein, and the growth signal stays switched on. Drugs that block HER2 can turn that signal off.

Less often, the HER2 gene has a mutação, a change in the gene itself rather than extra copies. A mutation is a different finding, and this article explains it later. These HER2 changes happen only in the cancer cells and are not inherited.

How common is HER2-positive colorectal cancer?

About 3 to 5 in 100 colorectal cancers are HER2-positive. HER2-positive colorectal cancers tend to share three features:

  • They start on the left side. Almost all start on the left side of the colon or in the rectum.
  • They have normal RAS and BRAF genes. HER2-positive cancers rarely have mutations in the KRAS, NRAS, ou IRMÃO genes. Your report may describe these genes as “wild-type,” which means no mutation was found.
  • They may not respond to anti-EGFR drugs. Cetuximab and panitumumab block a protein called EGFR. They often work less well in HER2-positive cancers.

Por que o teste é realizado?

HER2 testing in colorectal cancer is usually done when the cancer has spread. It helps your care team in two ways:

  • To see whether drugs that target HER2 may help. Two HER2-targeted treatments are approved for HER2-positive colorectal cancer that has spread.
  • To help choose other treatments. A HER2-positive cancer may respond poorly to anti-EGFR drugs, even when the RAS and BRAF genes are normal. Knowing the HER2 result helps your oncologist decide which drugs to use first.

Como o teste é realizado

HER2 testing in colorectal cancer is done on tissue from a biopsia or from surgery. Three kinds of tests can be used.

Imuno-histoquímica (IHC)

Imuno-histoquímica (IHC) stains the HER2 protein on a thin slice of the tumor so it can be seen under the microscope. A patologista Analisa a intensidade da coloração na borda das células cancerígenas e atribui uma pontuação de 0, 1+, 2+ ou 3+.

Laboratories use slightly different rules for how many cancer cells must be stained. Some require more than half of the cells to be stained. Others use a lower cut-off of 10% of the cells. In practice, both approaches almost always give the same final answer.

Hibridização in situ (ISH ou FISH)

Hibridação in situ (ISH) Conta as cópias do gene HER2 dentro das células cancerígenas. Uma forma comum é chamada de PEIXE. ISH is usually done when the IHC score is 2+. The report says the gene is either “amplified,” meaning extra copies are present, or “not amplified.”

Sequenciamento de próxima geração (NGS)

In colorectal cancer that has spread, a single sequenciamento de próxima geração (NGS) test often checks many genes at once, including KRAS, NRAS, BRAF, and HER2. NGS can detect extra copies of the HER2 gene and HER2 mutations. In colorectal cancer, extra copies found by NGS on tumor tissue can be enough to show that the cancer is HER2-positive.

NGS can also be done on a blood sample, called a biopsia liquida. Your care team will decide whether a blood result needs to be confirmed on tissue.

Como os resultados são relatados

HER2 results in colorectal cancer may appear in your pathology report, a separate molecular report, or both:

  • HER2-negative (score 0 or 1+). The cancer has little HER2.
  • HER2 equivocal (score 2+). The result is borderline. ISH or NGS is done next to give a clear answer.
  • HER2-positive (score 3+, or 2+ with an amplified gene). The cancer has too much HER2 or extra copies of the gene.
  • HER2 (ERBB2) amplification on NGS. The molecular report shows extra copies of the gene. ERBB2 is another name for the HER2 gene. In colorectal cancer, this usually counts as HER2-positive.
  • HER2 (ERBB2) mutation on NGS. A change was found in the gene itself. This is not the same as being HER2-positive.

O que significa o resultado

HER2-negativo

A HER2-negative colorectal cancer is not expected to respond to drugs that target HER2. This is the most common result. Treatment is guided by your other test results, including RAS, BRAF, and reparo de incompatibilidade (MMR), and by the cancer stage.

HER2 duvidoso (pontuação 2+)

A borderline HER2 result in colorectal cancer means the first test could not give a clear answer. ISH or NGS then decides. If the gene is amplified, the cancer is HER2-positive. If not, it is HER2-negative.

HER2-positivo

A HER2-positive colorectal cancer depends partly on HER2 to grow, so drugs that target HER2 may help. Because these cancers usually have normal RAS and BRAF genes, anti-EGFR drugs might seem like a good choice. HER2 can make those drugs work less well, and your oncologist will weigh this when planning treatment.

HER2 mutation

About 4 in 100 colorectal cancers have a HER2 mutation. The approved HER2 treatments are for HER2-positive cancer, not for HER2 mutations. Clinical trials are studying treatments for HER2-mutant cancers, and your oncologist can tell you whether one may be an option.

Tratamentos associados a resultados HER2-positivos

The US Food and Drug Administration (FDA) has approved drugs that target HER2 in colorectal cancer. They are used after other treatment, for cancer that cannot be removed with surgery or has spread. Approvals in other countries may differ.

  • Tucatinib (Tukysa) with trastuzumab (Herceptin). Trastuzumab blocks HER2 from outside the cell, and tucatinib is a pill that blocks it from inside. This combination is used for HER2-positive cancer with normal RAS genes that has grown after chemotherapy. In the main study, the cancer shrank in about 4 in 10 people.
  • Trastuzumab deruxtecan (Enhertu). This drug carries chemotherapy directly to cells that have HER2. It is approved for cancers with a HER2 score of 3+ after earlier treatment, regardless of the RAS result. In colorectal cancers with a score of 3+, the cancer shrank in about half of people.

Studies are now testing whether HER2-targeted drugs work better when given earlier, as part of first-line treatment. Ask your oncologist whether a clinical trial may be right for you.

HER2 and anti-EGFR treatment

HER2 matters for anti-EGFR treatment in colorectal cancer because it gives the cancer a second way to receive growth signals. Cetuximab and panitumumab block EGFR, but not HER2. A HER2-positive cancer can keep growing through HER2 even while EGFR is blocked. This is why many oncologists check HER2 before choosing anti-EGFR treatment.

O status HER2 tem implicações hereditárias?

HER2 changes in colorectal cancer happen only in the cancer cells and are not inherited. A HER2 result does not mean your family members have a higher risk of cancer. Inherited risk for colorectal cancer is checked in other ways, mainly through MMR testing for Síndrome de Lynch.

O que acontece depois

What happens after HER2 testing in colorectal cancer depends on the final result:

  • Se HER2-negativo. Medicamentos que têm como alvo o HER2 não fazem parte do plano de tratamento. Os resultados dos seus outros exames e o estágio do câncer orientarão o tratamento.
  • Se houver dúvidas (pontuação 2 ou superior). ISH or NGS is done, and your care team explains the next steps once the result is ready.
  • Se HER2-positivo. Your oncologist will talk with you about whether tucatinib with trastuzumab or trastuzumab deruxtecan may be options, now or later. They will also explain how the result affects anti-EGFR treatment.
  • Suppose a HER2 mutation was found. Your oncologist will explain what it means and whether a clinical trial may be available.

HER2 can differ between the original tumor and the sites where the cancer has spread. If the cancer grows or a new biopsy is taken, doctors may test HER2 again.

Perguntas para fazer ao seu médico

  • Was my colorectal cancer tested for HER2, and what was the result?
  • Which test was used: IHC, ISH, NGS, or a blood test?
  • If my score was 2+, has ISH or NGS been done?
  • Did NGS find extra copies of the HER2 gene or a HER2 mutation?
  • Are my KRAS, NRAS, and BRAF genes normal?
  • Does my HER2 result affect whether anti-EGFR treatment is a good choice for me?
  • If my cancer is HER2-positive, could tucatinib with trastuzumab or trastuzumab deruxtecan be options?
  • Are these treatments approved and covered where I live?
  • Could HER2 explain why my cancer stopped responding to cetuximab or panitumumab?
  • Should HER2 be tested again if the cancer grows?
  • Are there clinical trials of HER2-targeted treatment that I might qualify for?

Artigos relacionados em MyPathologyReport.com

A+ A A-
Esse artigo foi útil?